Main Menu
Main Menu
The news items below include announcements from companies in the Brain Tumor Investment Fund™ portfolio. These announcements are produced by the companies themselves. Their content, including any forward-looking or investigational claims, is the responsibility of the issuing company. Brain Tumor Investment Fund™ and National Brain Tumor Society do not specifically endorse or verify third-party statements, and investigational therapies referenced have not been proven safe or effective and are not approved by the U.S. Food and Drug Administration.
Accelerating Glioblastoma Therapeutics via Venture Philanthropy Abstract Development of curative treatments for glioblastoma (GBM) has been stagnant in recent decades largely because of significant financial risks. A portfolio-based strategy for the parallel discovery of breakthrough therapies can effectively reduce the financial risks of potentially transformative clinical trials for GBM. Using estimates from domain experts at the National Brain Tumor Society (NBTS), […] March 27, 2021
DelMar Pharmaceuticals Receives $500,000 Loan from the National Brain Tumor Society and National Foundation for Cancer Research to Support VAL-083’s Participation in a Pivotal Study for Glioblastoma Sponsored by the Global Coalition for Adaptive Research SAN DIEGO, June 24, 2020 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies announced today it has received a $500,000 loan from the National Brain Tumor Society (NBTS) and the National Foundation for Cancer Research (NFCR) to support VAL-083’s preparation forparticipation in […] June 24, 2020